Analyst Daniel Grosslight of Citi maintained a Buy rating on GoodRx Holdings (GDRX – Research Report), retaining the price target of $6.75.
Daniel Grosslight’s rating is based on GoodRx Holdings’ strong financial performance in the first quarter of 2025, which exceeded expectations in several key areas. The company’s revenue increased by 2.6% year-over-year, aligning with guidance and surpassing both Citi and consensus estimates. Notably, the adjusted EBITDA showed significant improvement, expanding by 266 basis points year-over-year and exceeding the high end of guidance by approximately $2 million.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.